|
RJV Networks, Inc. (OTC BB:
RJNV)
TARGET
Price $4 -to- $6 in January 2003
Tonight: RJNV holds
exclusive licenses to state-of-the-art bio-technology developed at University
of Michigan and the Cancer Control
Agency of B.C. that experts are using to develop therapies believed to be
capable of treating most cancers.
Through an acquisition of BioKinetix
Research, Inc. (currently underway), RJVN is rapidly completing the development
of a therapy for cancer that will make a lasting impression on the
multibillion dollar bio-tech industry. Read more about this exciting up and
comer below.
|
Company Name RJV Networks,
Inc.
Symbol
RJVN
Current Price $0.26
52 Week High
$2.10
52 Week
Low
$0.26
Target $4 -to-
$6 Q1/2003
|
Investment Highlights
ÿFFFFB7
RJVN projects
it will be able to treat most cancers with its combined targeted therapy
treatment which is based upon an astounding discovery by a molecular
biologist at the Univ. of Michigan
- The causal link to breast and most other malignancies and cancers in the
protein Mammastatin.
ÿFFFFB7
ÿFFFFB7
RJVN
has developed a series of cancer treatment therapies which utilize pan-cancer
market antibodies. Antibody therapies do not create chemical toxicity and, as
such, are fast tracked through the regulatory approval process. Using
this approach, RJVN is targeted to enter testing for its products in six
months.
ÿFFFFB7
ÿFFFFB7
RJVN's combination of two leading, well known technologies previously
announced by BioCurex and InNexus Corp along with RJVN's key MAb protein
replicating technology has allowed the Company to create a series of patented
therapeutic products that many molecular biologists believe will treat
most cancers.
ÿFFFFB7
ÿFFFFB7
RJVN's R&D and Management are led by Dr. John Todd, Dr.
Charles Morgan (a world renowned molecular biologist and 5 other industry
leading Dr's all with several years experience in bio-tech development.
RJVN (through BioKinetix Research, Inc.) was formed
after Dr. John Todd, a very well known and respected oncological surgeon from
BC, approached us with the story of an astounding discovery that had been
made by molecular biologists at the University of Michigan. This
discovery was believed to be the causal link to breast cancer, the link is a
medium sized (53KD) protein called Mammastatin. The evidence is that
Mammastatin is the agent that, when present, prevents the development and
growth of malignant breast tumors. Mammastatin is freely expressed by the
epithelial cells in the breast and as such acts as a natural contra-agent to
malignant development. Women who develop breast cancer have NO or
extremely low levels of Mammastatin in their system. After testing
hundreds of women, no woman with normal Mammastatin levels has developed
breast cancer.
Dr. John Todd in conjunction with the Cancer Control
Agency of B.C. conducted compassionate trials on several terminally ill
patients (authorized by Health Canada)
with a Mammastatin replacement program the results of which thoroughly
convinced Dr. Todd of the direct link. The challenge existed from the
fact that proteins are extremely difficult to sequence (replicate).
Mammastatin has over 400 amino-acids in its chain, and, even if successful in
sequencing, the synthetic replication is even more difficult. Finally
the delivery of a protein, natural or synthetic, will now have to face the natural
breakdown of the chain as it circulates through the body.
Dr. Charles Morgan is a world-renowned molecular
biologist who has proposed an alternative approach to this problem. He
is convinced, and several well known molecular biologists agree with him,
that he can mimic the active component of the Mammastatin protein through the
production of an anti-idiotypic monoclonal antibody (MAb). These MAbs
are stable, target specific and will in all measure act like the native
Mammastatin. To dramatically enhance the bio-activity of these
anti-idiotypic monoclonal antibodies, RJNV will create Superantibodies
through the use of InNexus' Super Antibody platform technology (see news for OTC BB: BOCX about this
technology). This technology allows the cross linking of antibodies to boost
their potency and resiliency.
As a result of the scientific approach implemented by
RJNV's BioKinetix (acquisition underway), the company has negotiated a
license from BioCurex OTC BB:
BOCX to develop therapeutic products based on their pan-cancer marker
antibodies. The combination of these two technologies gives RJVN the
potential to create a series of therapeutic products that will treat most
cancers.
Antibody therapies do not create chemical toxicity and,
as such, are fast tracked through the regulatory approval process. Using
this approach, RJVN is targeted to enter testing for its products in six
months.
The potential market for RJVN's cancer treatment
therapies far outstrips any reasonable estimate to be made at this
time. As the Company implements its technology upon entering the market
test phase, we expect a large bio-tech or pharmaceutical mfr. to acquire the
Company for several hundred million.
Due to the Companies ability to fast track, beginning
clinical trials of its revolutionary cancer treatment in early 2003E,
exposure of its initial success will spread quickly.
The Company will be participating in a road-show in
January and February of 2003, meeting with several institutional brokerage
houses in San Francisco, New York,
and other major metro areas to showcase their technology. We expect
many pension fund managers to begin positioning the stock in their portfolios
sometime in Q1/2003 and Q2/2003.
The stock is highly undervalued currently due to the
fact that there has been no P/R done on the Company. Mass direct mail,
investment club profiles and other P/R related activities are beginning with
the issuance of this newsletter. We expect the stock to appreciate
significantly over the next 20-trading days.
TARGET Price $4 -to- $6 in January 2003
|
